JP2024525843A5 - - Google Patents

Info

Publication number
JP2024525843A5
JP2024525843A5 JP2024502438A JP2024502438A JP2024525843A5 JP 2024525843 A5 JP2024525843 A5 JP 2024525843A5 JP 2024502438 A JP2024502438 A JP 2024502438A JP 2024502438 A JP2024502438 A JP 2024502438A JP 2024525843 A5 JP2024525843 A5 JP 2024525843A5
Authority
JP
Japan
Prior art keywords
glu
lys
pharmaceutically acceptable
acceptable salt
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024502438A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024525843A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/073793 external-priority patent/WO2023288313A1/en
Publication of JP2024525843A publication Critical patent/JP2024525843A/ja
Publication of JP2024525843A5 publication Critical patent/JP2024525843A5/ja
Pending legal-status Critical Current

Links

JP2024502438A 2021-07-16 2022-07-15 マルチアゴニストペプチドを含む組成物並びに製造及び使用方法 Pending JP2024525843A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163222747P 2021-07-16 2021-07-16
US63/222,747 2021-07-16
PCT/US2022/073793 WO2023288313A1 (en) 2021-07-16 2022-07-15 Compositions including multi-agonist peptides and methods of manufacture and use

Publications (2)

Publication Number Publication Date
JP2024525843A JP2024525843A (ja) 2024-07-12
JP2024525843A5 true JP2024525843A5 (cg-RX-API-DMAC7.html) 2025-07-24

Family

ID=84919777

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024502438A Pending JP2024525843A (ja) 2021-07-16 2022-07-15 マルチアゴニストペプチドを含む組成物並びに製造及び使用方法

Country Status (6)

Country Link
US (1) US20230203100A1 (cg-RX-API-DMAC7.html)
EP (1) EP4370537A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024525843A (cg-RX-API-DMAC7.html)
AU (1) AU2022311018A1 (cg-RX-API-DMAC7.html)
CA (1) CA3226003A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023288313A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240059753A1 (en) * 2022-07-15 2024-02-22 Pep2Tango Therapeutics Inc. Compositions including multi-agonist peptides and methods of manufacture and use
AU2024218747A1 (en) * 2023-02-10 2025-08-28 Hangzhou Sciwind Biosciences Co., Ltd. Polypeptide and derivative thereof, composition, and use thereof
TWI926512B (zh) * 2023-11-30 2026-05-21 丹麥商諾佛 儂迪克股份有限公司 Glp-1、gip及澱粉素受體之三重促效劑
US20250236656A1 (en) * 2023-12-12 2025-07-24 Amide Technologies Multimeric polypeptides and uses thereof
TW202600132A (zh) 2024-03-08 2026-01-01 美商安尼波那生物公司 用於治療肥胖症及提高減重之方法
KR102966075B1 (ko) * 2024-11-19 2026-05-19 (주)케어젠 항비만 및 항당뇨 활성을 갖는 펩타이드 및 이의 용도
KR102991397B1 (ko) 2024-11-29 2026-07-21 노보 노르디스크 에이/에스 Glp-1, gip, 및 아밀린 수용체의 삼중작용제 및 이의 용도

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2597649A1 (en) * 2005-02-11 2006-08-17 Amylin Pharmaceuticals, Inc. Gip analog and hybrid polypeptides with selectable properties
US8598314B2 (en) * 2007-09-27 2013-12-03 Amylin Pharmaceuticals, Llc Peptide-peptidase-inhibitor conjugates and methods of making and using same
SI2864350T1 (en) * 2012-06-21 2018-08-31 Indiana University Research And Technology Corporation GLUCAGON ANALOGUE ANALOGUE WITH ACTIVITY OF GIP RECEPTOR
EP3856768A2 (en) * 2018-09-24 2021-08-04 Takeda Pharmaceutical Company Limited Gip receptor agonist peptide compounds and uses thereof
IL296219A (en) * 2020-03-25 2022-11-01 Takeda Pharmaceuticals Co Qw dosing of gip receptor agonist peptide compounds and uses thereof

Similar Documents

Publication Publication Date Title
JP2023002662A5 (cg-RX-API-DMAC7.html)
CN111263586B (zh) 乙型肝炎抗病毒剂
JP2023526973A5 (cg-RX-API-DMAC7.html)
RU2006109187A (ru) Агонисты рецептора меланокортина
JP2025163134A5 (cg-RX-API-DMAC7.html)
JP2023078367A5 (cg-RX-API-DMAC7.html)
JP2013517307A5 (cg-RX-API-DMAC7.html)
CA2776302A1 (en) Neuropeptide-2 receptor (y-2r) agonists
JP2013523618A5 (cg-RX-API-DMAC7.html)
CN109925312A (zh) 用于治疗眼病的组合物、制剂和方法
JP2022504596A5 (cg-RX-API-DMAC7.html)
EP0456758A1 (en) Anaphylatoxin-receptor ligands
JP2022543826A5 (cg-RX-API-DMAC7.html)
CA3211494A1 (en) Protein-drug conjugates for antiviral therapy
JP2023533162A5 (cg-RX-API-DMAC7.html)
WO2023086028A2 (en) Allenamide linkers for antibody-drug conjugate
KR20120125610A (ko) 시클로스포린 유사체
CN105348345A (zh) 一种含有硫普罗宁结构的前药、其制备方法、药物组合物及其用途
WO2000054808A1 (fr) Agoniste du recepteur ep4 de la prostaglandine et traitement correspondant
JP2022501364A5 (cg-RX-API-DMAC7.html)
JP2023537895A5 (cg-RX-API-DMAC7.html)
JP2025166052A (ja) 肥満の治療における使用のためのil-4由来ペプチド
US6426330B1 (en) Satiety inducing composition comprising Neuropeptide Y analogues and methods of inducing satiety and treating a disease or condition associated with it
JP2023524274A5 (cg-RX-API-DMAC7.html)
JP2022521474A5 (cg-RX-API-DMAC7.html)